- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Ontreatment HbsAg Kinetics with Newer Combination Therapy in Genotype D, Envelope Antigen Negative Chronic Hepatitis B - Interim Analysis
Vadamalainathan Govindasamy, Mohanprasad Virukalpattigopalratnam
Department of Clinical Research, VGM Hospital-Institute of Gastroenterology, Coimbatore, India
Background and aims: HBsAg levels appear to correlate with transcriptionally active cccDNA and HBsAg seroclearance is considered to be the closest to cure in Chronic Hepatitis B and is also associated with a favourable long term outcome. Aim of present study is to assess HBsAg kinetics including HBsAg loss in two combination therapies in HBeAg negative CHB.
Methods: Twenty consecutive patients with HBeAg negative, Genotype D CHB were randomized to two arms. Patients in Arm A received PEG Interferon alpha-2b 1.5mcg/kgbw S/c once weekly along with oral Tenofovir 300mg per day for 48 weeks followed by Tenofovir alone for another 96 weeks. Patients in Arm B received a combination of Telbivudine 600mg with Tenofovir 300mg per day for 144 weeks. Quantification of HBsAg and HBV DNA were performed at baseline and six monthly intervals till 144th Week.
Results: Baseline characteristics were comparable in both the arms. After 48 weeks of treatment, ten patients (100%) in Arm A had undetectable HBV DNA compared to nine pts(90%) in Arm B. ALT normalization was achieved in 10/10 patients in arm A vs 7/10 pts in Arm B. Mean HBsAg decline from baseline was higher in Arm A than Arm B (1.85 vs 0.64 ,p =0.000). No Serious adverse events were noted in either of the groups.
Conclusion: On therapy Decline in HBsAg levels was highest in Interferon therapy arm than Nucleoside analogs arm reinforcing the fact that HBsAg decline is effected more by immune modulation than antiviral effect. The combination of Tenofovir with Peg Interferon has shown greater efficacy in terms of HBV DNA negativity , ALT normalisation as well as reduction in HBsAg levels. However the translation of these positive findings into sustained viral response and HBsAg loss needs to be seen since this is only an interim data.
Assigned speakers:
Dr. Vadamalainathan Govindasamy, VGM Hospital-Institute of Gastroenterology , Coimbatore , India
Assigned in sessions:
07.06.2013, 08:30-17:30, PT-4, HEP B Clinical, Exhibition Hall
|
|